According to RIA Novosti, the ministry registered the original drugs "Aykyrvo" (elafibranor) and "Gempavzi" (marstacimab). The agency published this information citing the Ministry of Health's press service.
Elafibranor is intended for adult patients with primary biliary cholangitis – a rare chronic liver disease. In early November, the Ministry of Health included this disease in the list of orphan diseases, RIA Novosti reported.
"Gempavzi" is used for the prevention of bleeding in severe hemophilia A or B in patients aged 12 years and older, if they do not have inhibitors of blood clotting factors and their body weight is at least 35 kg, the agency writes.
The registration of the drugs concerns different patient groups: adults with cholangitis are prescribed elafibranor, while marstacimab is used for the prevention of bleeding in severe hemophilia. The announcement does not contain data on the consequences of registration for drug availability or the timing of their arrival at medical institutions.